The Latest Cardiac and Vascular News
Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and AA genotype at variant rs1967309 in the ADCY9 gene. LONDON and MONTREAL, July 21, 2022 (GLOBE NEWSWIRE) — DalCor Pharmaceuticals announced the results of the […]
End of study brings Robocath closer to commercializing R-One in China in 2023 149 patients enrolled over six months in four Chinese centers Results of first vascular robotics study on this scale in China will be published in March 2023 Rouen, France, July 20, 2022 – Robocath, a company that […]
Pelacarsen is a potentially first-in-class treatment specifically targeting elevated lipoprotein(a) (Lp(a)), an independent, inherited and causal risk factor for cardiovascular disease There are currently no approved pharmacological therapies to effectively lower Lp(a), which cannot be effectively addressed by diet and other lifestyle changes Topline results expected 2025 CARLSBAD, Calif., July 20, 2022 /PRNewswire/ — Ionis […]
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the dosing of the first patient in their multicenter Phase 2 trial assessing efficacy and safety of CDR132L in 280 patients with reduced left ventricular ejection fraction after myocardial infarction […]
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA Ii with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US INDii filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in validated clinical measures Heart failure disease-modifying profile – safe, rapid and effective decongestion with no congestion-related heart failure re-hospitalizations observed […]
Expanded Access for 125,000 American Lives for Highly Accurate, Novel Blood Tests KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc. today announces that Atlas Genomics, Prevencio’s performing laboratory for its Artificial Intelligence (AI)-driven cardiac HART blood tests, has entered into a preferred provider agreement with Alivio Health to provide expanded access for Prevencio’s HART tests. The coverage includes […]
Partnership Reinforces USHV’s Strong Position in Houston and Supports Long-Term Goals for National Footprint Expansion NASHVILLE, Tenn.–(BUSINESS WIRE)–US Heart & Vascular (“USHV”), the leading national provider of support services to cardiovascular physician practices, announced today that it has signed a definitive agreement regarding its partnership with Willowbrook Cardiovascular Associates (“Willowbrook”), […]
CARDINAL-HF is the first Phase 2 proof-of-concept trial of a PDE9 inhibitor in heart failure Large-scale trial builds upon encouraging data generated in Cardurion’s Phase 1b trial CARDINAL-HF will examine the effects of CRD-740, Cardurion’s PDE9 inhibitor, in both types of heart failure and in key subsets of these patients […]
SHANGHAI, July 15, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized device pioneer in the treatment for cardiopulmonary diseases, today announced that it has successfully concluded the first Pre-Sub meeting with the U.S. Food and Drug Administration (“FDA”) for its Pulmonary Artery Denervation (PADN) Global Trial. Dr. Shaoliang Chen, Chair of Pulnovo […]
Evolut FX TAVR System Used to Treat Patient with Symptomatic Severe Aortic Stenosis LOS ANGELES, July 13, 2022 /PRNewswire/ — PIH Health Good Samaritan Hospital is the first hospital in Los Angeles to treat patients with the next-generation, self-expanding Evolut FX Transcatheter Aortic Valve Replacement (TAVR) System, a minimally invasive alternative to open-heart surgical aortic […]
